Elite Pharmaceutical (ELI) and ECR Launch Second Once-Daily Antihistamine
More News related to ELI
- Oppenheimer Starts Elite Pharma (ELI) at Buy
- Boenning & Scattergood Starts Elite Pharmaceuticals (ELI) at Market Outperform
- Elite Pharmaceuticals (ELI) Provides Positive Clinical Update
- Elite Pharmaceutical (ELI) and ECR Launch Second Once-Daily Antihistamine
- Elite Pharmaceuticals (ELI) Announces Strategic Alliance with Dr. Veerappan Subramanian
More News related to FDA
- Unilever (UL) Annouces Total Recall of Slim-Fast Cans
- Steris (STE) Sinks After FDA Notice on Concerns About the Steris System 1 Processor
- Watson Pharmaceuticals (WPI) Files New Drug Application with FDA for Generic Rozerem
- St. Jude (STJ) Receives U.S. FDA Approval for Penta Surgical Lead
- AstraZeneca (AZN) Gets U.S. FDA Approval for SEROQUEL XR Antidepressants
Elite Pharmaceutical, Inc.'s (AMEX: ELI) marketing partner, ECR Pharmaceuticals, has launched Elite's second once-a-day allergy product, under ECR's brand LODRANE 24D, an extended release formulation of brompheniramine maleate and pseudoephedrine HCl.
Lodrane 24D utilizes Elite's proprietary extended release technology to provide once-daily dosing of an effective, low-sedating antihistamine combined with a decongestant.
Elite Pharmaceuticals will manufacture the product and will receive a royalty on product revenues. The current U.S. allergy market exceeds $3 billion.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
